Henshaw Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Henshaw Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,820	Closed	-$80K	–	270
2022 Q4	$80K	Hold	10,820	–	–	0.01%	249
2022 Q3	$107K	Hold	10,820	–	–	0.01%	293
2022 Q2	$118K	Sell	10,820 -3,531	-25%	-$36.6K	0.01%	300
2022 Q1	$162K	Hold	14,351	–	–	0.01%	313
2021 Q4	$225K	Hold	14,351	–	–	0.01%	309
2021 Q3	$246K	Hold	14,351	–	–	0.02%	289
2021 Q2	$309K	Hold	14,351	–	–	0.02%	276
2021 Q1	$216K	Hold	14,351	–	–	0.01%	326
2020 Q4	$189K	Hold	14,351	–	–	0.01%	332
2020 Q3	$139K	Hold	14,351	–	–	0.01%	307
2020 Q2	$164K	Hold	14,351	–	–	0.01%	301
2020 Q1	$149K	Buy	+14,351	New	+$178K	0.01%	268
2019 Q4	–	Sell	-10,572	Closed	-$140K	–	302
2019 Q3	$140K	Buy	+10,572	New	+$147K	0.01%	278
2019 Q1	–	Sell	-9,705	Closed	-$254K	–	296
2018 Q4	$254K	Buy	+9,705	New	+$228K	0.02%	208

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Henshaw Capital's VNDA Position: Q1 2023 in Review

Henshaw Capital sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 10,820 shares — an estimated $80K sold.

Henshaw Capital first reported a position in VNDA in Q4 2018 and held it in 14 quarters. The position peaked at $309K in Q2 2021. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

Henshaw Capital reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Henshaw Capital sold 10,820 Vanda Pharmaceuticals shares in Q1 2023, an estimated $80K.
Henshaw Capital first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 14 quarters.
Henshaw Capital's Vanda Pharmaceuticals position peaked at $309K in Q2 2021.
177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Henshaw Capital's 13F filing for Q1 2023, filed 28 May 2026.